Abstracts tagged "genetics"

Abstract Number: 99 • 2015 ACR/ARHP Annual Meeting
Personalised Genetic Medicine: HLA-DRB1 Amino Acid Positions 11, 71 and 74 Predict Inflammation Level, Disease Activity and Disability in Rheumatoid Arthritis
Stephanie Ling¹, Sebastien Viatte², Mark Lunt³, Alper van Sijl⁴, Lucía Silva Fernández^4,5, Soumya Raychaudhuri^2,6,7, Deborah P.M. Symmons^4,8, Adam Young^9,10, Alex J Macgregor¹¹ and Anne Barton¹², ¹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Mancheser Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁵Rheumatology, Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain, ⁶Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, ⁸Centre for Musculoskeletal Research, University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ⁹Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom, ¹⁰School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ¹¹School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, United Kingdom, ¹²Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom
Background/Purpose: Amino acid (AA) positions 11, 71 and 74 inside HLA-DRB1 confer susceptibility to rheumatoid arthritis (RA). AAs from these positions form 16 haplotypes, hierarchically…
Abstract Number: 109 • 2015 ACR/ARHP Annual Meeting
Association of HLA-G and Leukocyte Immunoglobulin-like Receptor A3 Polymorphisms with the Susceptibility to Pulmonary Hyterpention in Systemic Sclerosis
Yuki Hachiya¹, Aya Kawasaki¹, Takashi Matsushita², Hiroshi Furukawa¹, Shouhei Nagaoka³, Kota Shimada⁴, Shoji Sugii⁴, Keigo Setoguchi⁵, Akira Okamoto⁶, Noriyuki Chiba⁷, Eiichi Suematsu⁸, Masao Katayama⁹, Shunsei Hirohata¹⁰, Hajime Kono¹¹, Kiyoshi Migita¹², Takayuki Sumida¹³, Shigeto Tohma¹⁴, Minoru Hasegawa¹⁵, Manabu Fujimoto¹⁶, Shinichi Sato¹⁷, Kazuhiko Takehara¹⁸ and Naoyuki Tsuchiya¹⁹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa city, Japan, ³Rheumatology, Yokohama Minami Kyosai Hospital, Yokohama, Japan, ⁴Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, ⁵Department of Allergy and Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, ⁶Department of Rheumatology,, Himeji Medical Center, National Hospital Organization, Himeji, Japan, ⁷Department of Rheumatology, Morioka National Hospital, NHO, Iwate, Japan, ⁸Department of Internal Medicine and Rheumatology, National Hospital Organization, Kyushu Medical Research Center, Fukuoka, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Nagoya Medical Center, National Hospital Organization, Nagoya City, Aichi, Japan, ¹⁰Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ¹¹Department of Internal Medicine, Teikyo University, Tokyo, Japan, ¹²Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, ¹³Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹⁴Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ¹⁵Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan, ¹⁶Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ¹⁷Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ¹⁸Dermatology, Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa city, Japan, ¹⁹Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Human leukocyte antigen-G (HLA-G) is a non-classical class I molecule expressed in the immune cells, the spleen, and the lungs, and plays a key…
Abstract Number: 513 • 2015 ACR/ARHP Annual Meeting
Cumulative Association of Genetic Variants with Rheumatoid Joint Damage Progression in Mexican Americans and European Americans
Rector Arya¹, Inmaculada del Rincon², Jose Felix Restrepo³, Vidya S Farook⁴, Christopher P Jenkinson⁵, Ravindranath Duggirala⁶ and Agustin Escalante⁷, ¹Pediatrics, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁴Genetics, Texas Biomedical Research Institute, San Antonio, TX, ⁵University of Texas Health Science Center at San Antonio, San Antonio, TX, ⁶Regional Academic Health Center, Harlingen, TX, ⁷Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Genealogical and genetic association studies have suggested that joint damage in rheumatoid arthritis (RA) may be heritable. We and others have found a number…
Abstract Number: 1210 • 2015 ACR/ARHP Annual Meeting
Genetic, Environmental, and Serologic Risk Factors for Inflammatory Joint Signs Among First-Degree Relatives without Rheumatoid Arthritis in a Prospective Cohort
Jeffrey A. Sparks¹, Shun-Chiao Chang², Kevin D. Deane³, Ryan W. Gan⁴, Kristen Demoruelle³, Marie L. Feser³, LauraKay Moss³, Jane H. Buckner⁵, Richard M. Keating⁶, Karen H. Costenbader⁷, Peter K. Gregersen⁸, Michael H. Weisman⁹, Ted R. Mikuls¹⁰, James R. O'Dell¹⁰, V. Michael Holers³, Jill M. Norris⁴ and Elizabeth W. Karlson², ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Division of Rheumatology, Scripps Health, La Jolla, CA, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁸Feinstein Insititute for Medical Research, Manhasset, NY, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Family history of RA in a first-degree relative increases RA risk 4-fold. Determining risk factors for inflammatory joint signs (IJS) in this high risk…
Abstract Number: 1402 • 2015 ACR/ARHP Annual Meeting
Development of Systemic Juvenile Idiopathic Arthritis Manifestations Following Remission of Hemophagocytic Lymphohistiocytosis
Baruch Goldberg¹, Eyal Muscal², Marietta De Guzman³ and Carl Allen⁴, ¹Pediatric Rheumatology, Texas Children's Hospital, Houston, TX, ²Pediatric Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Hematology and Oncology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal pathologic inflammatory process resulting from impaired immune function due to inherited gene mutations or secondary to…
Abstract Number: 1632 • 2015 ACR/ARHP Annual Meeting
Do RA Susceptibility Loci Predict Response to Methotrexate As First DMARD in Early RA?
Thomas Frisell¹, Saedis Saevarsdottir^2,3 and Johan Askling^1,4, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Improved means to predict which RA patients will respond to methotrexate monotherapy, the preferred first line therapy in early RA, would allow patients to…
Abstract Number: 1929 • 2015 ACR/ARHP Annual Meeting
Somatic Mutations in Clonally Expanded Cytotoxic Lymphocytes in Patients with Newly Diagnosed Rheumatoid Arthritis
Paula Savola¹, Tiina Kelkka¹, Hanna Rajala¹, Antti Kuuliala², Krista Kuuliala², Samuli Eldfors³, Pekka Ellonen³, Sonja Lagstrom³, Rajiv Kumar Khajuria¹, Taina Jaatinen⁴, Riitta Koivuniemi⁵, Heikki Repo², Janna Saarela³, Kimmo Porkka¹, Marjatta Leirisalo-Repo⁶ and Satu Mustjoki¹, ¹Department of Hematology, Hematology Research Unit Helsinki, University of Helsinki, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, ²Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland, ³Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, ⁴Clinical Laboratory, Finnish Red Cross Blood Service, Helsinki, Finland, ⁵Department of Medicine, Division of Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁶Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: In rheumatoid arthritis (RA), the mechanisms initiating immune dysregulation leading to joint damage are incompletely understood. Previous studies show that large CD8+ T cell…
Abstract Number: 2101 • 2015 ACR/ARHP Annual Meeting
HLA Associations in Mothers of Children with Cardiac Manifestations of Neonatal Lupus
Hannah C. Ainsworth¹, Carl D. Langefeld¹, Miranda C. Marion², Nathalie Costedoat-Chalumeau³, Antonio Brucato⁴, Jill P. Buyon⁵ and Robert M. Clancy⁵, ¹Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ²Biostatistical Sciences and Center for Public Health Genomics, Wake Forest University Health Sciences, Winston-Salem, NC, ³Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁴Internal Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy, ⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Cardiac manifestations of neonatal lupus, comprising atrioventricular conduction defects and cardiomyopathy, occur in fetuses exposed to anti-Ro/SSA antibodies, and carry substantial mortality. There is…
Abstract Number: 2702 • 2015 ACR/ARHP Annual Meeting
Immunophenotyping of Rheumatoid Arthritis Reveals the Linkage Between HLA-DRB1 Genotype, CXCR4 Expressions on Memory CD4+ T Cells, and Disease Activity
Yasuo Nagafuchi¹, Hirofumi Shoda¹, Shuji Sumitomo¹, Shinichiro Nakachi¹, Rika Kato², Yumi Tsuchida², Haruka Tsuchiya², Keiichi Sakurai², Norio Hanata², Shoko Tateishi², Hiroko Kanda², Keishi Fujio¹ and Kazuhiko Yamamoto¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: The HLA-DRB1 is the strongest genetic risk factor for rheumatoid arthritis (RA). Although this fact suggests a pivotal role for adaptive immunity in RA,…
Abstract Number: 2953 • 2014 ACR/ARHP Annual Meeting
International Immunochip Study in the Idiopathic Inflammatory Myopathies Identifies Novel Susceptibility Loci and Confirms HLA As Strongest Genetic Risk Factor
Simon Rothwell¹, Robert G. Cooper², Ingrid E. Lundberg³, Frederick W. Miller⁴, Peter K. Gregersen⁵, Jiri Vencovsky⁶, Katalin Danko⁷, Lucy R Wedderburn⁸, Vidya Limaye⁹, Albert Selva O'Callaghan¹⁰, Michael G. Hanna¹¹, Pedro Machado¹¹, Lauren M. Pachman¹², Ann M. Reed¹³, Lisa G. Rider⁴, Joanna Cobb¹, Hazel Platt¹⁴, Øyvind Molberg¹⁵, Olivier Benveniste¹⁶, Pernille Mathiesen¹⁷, Timothy Radstake¹⁸, Andrea Doria¹⁹, Jan De Bleecker²⁰, Boel De Paepe²¹, Britta Maurer²², William E. Ollier¹⁴, Leonid Padyukov³, Terrance P. O'Hanlon⁴, Annette Lee²³, Hector Chinoy¹ and Janine Lamb¹⁴, ¹Centre for Genetics and Genomics, Arthritis Research UK, University of Manchester, Manchester, United Kingdom, ²MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵The Feinstein Institute for Medical Research, Manhasset, NY, ⁶Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁷University of Debrecen, University of Debrecen, Debrecan, Hungary, ⁸Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁹Royal Adelaide Hospital, Adelaide, Australia, ¹⁰Vall d'Hebron General Hospital, Barcelona, Spain, ¹¹MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, ¹²Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, United Kingdom, ¹⁵Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ¹⁶Internal Medecine Dpt 1, Pitié-Salpêtrière Hospital, APHP, Paris, France, ¹⁷Paediatric Department, Holbaek University Hospital, Holbaek, Denmark, ¹⁸University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Department of Medicine - DIMED, University of Padova, Padova, Italy, ²⁰University of Ghent, Ghent, Belgium, ²¹Neuromuscular Reference Center, University of Ghent, Ghent, Belgium, ²²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²³Genomics & Human Genetics, Feinstein Institute Med Rsch, Manhasset, NY
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of rare autoimmune diseases characterised by muscle weakness and extramuscular manifestations such as skin rashes…
Abstract Number: 625 • 2014 ACR/ARHP Annual Meeting
Fine-Mapping Major Histocompatibility Complex Associations Identified Contribution of Multiple Class I and II HLA Genes on Risk of Psoriasis and Its Clinical Subtypes
Yukinori Okada¹, Buhm Han², Lam C. Tsoi³, Philip E. Stuart⁴, Eva Ellinghaus⁵, Trilokraj Tejasvi⁶, Vinod Chandran⁷, Fawnda Pellett⁸, Remy Pollock⁹, Anne M. Bowcock¹⁰, Gerald G. Krueger¹¹, Michael Weichenthal⁵, John J. Voorhees⁶, Proton Rahman¹², Peter K. Gregersen¹³, Andre Franke¹⁴, Rajan P. Nair⁶, Gonçalo R. Abecasis¹⁵, Dafna D. Gladman⁷, James T. Elder⁶, Paul IW. de Bakker¹⁶ and Soumya Raychaudhuri¹⁷, ¹Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ²Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, ³Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, ⁴Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Christian-Albrechts-University of Kiel, Kiel, Germany, ⁶University of Michigan Medical School, Ann Arbor, MI, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁰Imperial College, London, United Kingdom, ¹¹Dermatology, University of Utah, Salt Lake City, UT, ¹²Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ¹³The Feinstein Institute for Medical Research, Manhasset, NY, ¹⁴Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶University Medical Center, Utrecht, Netherlands, ¹⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Psoriasis vulgaris (PsV) risk is strongly associated with genetic variation within the major histocompatibility complex (MHC) region, although its fine genetic architecture has not…
Abstract Number: 2918 • 2014 ACR/ARHP Annual Meeting
Fine-Mapping Major Histocompatibility Complex Associations in ACPA-Positive Rheumatoid Arthritis Identified Shared HLA Amino Acid Polymorphisms in Asian and European Populations
Yukinori Okada¹, Kwangwoo Kim², Buhm Han³, Nisha E. Pillai⁴, Rick T-H. Ong⁴, Woei-Yuh Saw⁴, Ma Luo⁵, Lei Jiang⁶, Jian Yin⁶, So-Young Bang⁷, Hye-Soon Lee⁷, Matthew A. Brown⁸, Sang-Cheol Bae², Huji Xu⁹, Yik-Ying Teo⁴, Paul IW. de Bakker¹⁰ and Soumya Raychaudhuri³, ¹Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁴National University of Singapore, Singapore, Singapore, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶The Second Military Medical University, Shanghai, China, ⁷Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ⁸University of Queensland Diamantina Institute, Brisbane, Australia, ⁹Shanghai Changzheng Hospital, Shanghai, China, ¹⁰Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) risk is strongly associated with variations within the major histocompatibility complex (MHC) region, and in particular to HLA-DRB1 alleles. We aimed…
Abstract Number: 87 • 2014 ACR/ARHP Annual Meeting
Association of TRIM21 (RO52) Polymorphisms with Systemic Lupus Erythematosus in a Japanese Population
Misaki Hidaka¹, Aya Kawasaki¹, Hiroshi Furukawa², Yuya Kondo³, Satoshi Ito⁴, Isao Matsumoto⁵, Makio Kusaoi⁶, Hirofumi Amano⁶, Akiko Suda⁷, Keigo Setoguchi⁸, Tatsuo Nagai⁹, Kota Shimada¹⁰, Shoji Sugii¹⁰, Akira Okamoto¹¹, Noriyuki Chiba¹², Eiichi Suematsu¹³, Masao Katayama¹⁴, Akiko Okamoto¹⁵, Hajime Kono¹⁵, Shigeru Ohno⁷, Shunsei Hirohata¹⁶, Shouhei Nagaoka¹⁷, Yoshinari Takasaki¹⁸, Hiroshi Hashimoto¹⁹, Shigeto Tohma², Takayuki Sumida³ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ³Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁴Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ⁵Department of Interenal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁶Department of Rheumatology and Internal Medicine, Juntendo University, Tokyo, Japan, ⁷Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ⁸Allergy and Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, ⁹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ¹⁰Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ¹¹Department of Rheumatology,, Himeji Medical Center, National Hospital Organization, Himeji, Japan, ¹²Department of Rheumatology, Morioka Hospital, National Hospital Organization, Morioka, Japan, ¹³Department of Internal Medicine and Rheumatology, Clinical Research Institute, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan, ¹⁴Division of Rheumatology, Department of Internal Medicine, Nagoya Medical Center, National Hospital Organization, Nagoya City, Aichi, Japan, ¹⁵Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ¹⁶Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ¹⁷Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, ¹⁸Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁹Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose TRIM21, also referred to as Ro52 or SS-A1, belongs to the tripartite motif-containing (TRIM) family. TRIM21 is not only important as an autoantigen, but…
Abstract Number: 2841 • 2014 ACR/ARHP Annual Meeting
Identifying Novel Lupus Severity Risk Variants through Identification of Alleles with High Ethnic Variability Worldwide
Belinda A. Waltman¹, Kimberly E. Taylor², Julio Molineros³, Sarah French⁴, Joanne Nitiham¹, Jennifer Kelly³, Adam Adler⁵, Judith A. James³, Swapan Nath⁶, Marta Alarcon-Riquelme^3,7 and Lindsey A. Criswell¹, ¹Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴School of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷GENYO. Center for Genomics and Oncological Research, Granada, Spain
Background/Purpose: Substantial epidemiologic evidence demonstrates that SLE disproportionately affects minority patients in terms of incidence, prevalence, and disease severity. European ancestry has been associated with…
Abstract Number: 86 • 2014 ACR/ARHP Annual Meeting
Association of Leukocyte Immunoglobulin-like Receptor A3 (LILRA3) with Systemic Sclerosis
Yuki Hachiya¹, Aya Kawasaki¹, Takashi Matsushita², Hiroshi Furukawa³, Shouhei Nagaoka⁴, Kota Shimada⁵, Shoji Sugii⁵, Takayuki Sumida⁶, Shigeto Tohma³, Minoru Hasegawa⁷, Manabu Fujimoto⁸, Shinichi Sato⁹, Kazuhiko Takehara¹⁰ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Deramtology, Kanazawa University, Kanazawa, Japan, ³Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁴Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, ⁵Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁶Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁷Dermatology, University of Fukui, Yoshida-gun, Fukui, Japan, ⁸Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁹Department of Dermatology, The University of Tokyo, Tokyo, Japan, ¹⁰Dermatology, Kanazawa University, Kanazawa, Japan
Background/Purpose: The leukocyte immunoglobulin-like receptors (LILRs) are a gene family located in leukocyte receptor complex at 19q13.4. LILRs are expressed mainly in immune cells as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.